EARLY DEVELOPMENTAL DIFFERENCES BETWEEN DSM-III-R SCHIZOPHRENICS TREATED WITH CLOZAPINE AND TYPICAL NEUROLEPTICS

Developmental deviance is known to be associated with schizophrenia. W e tested the hypothesis that the most severe schizophrenia requiring t reatment with clozapine would particularly show these effects. Therefo re, associative factors from pregnancy, delivery, neonatal and socio-d emographic characteristics were compared between the clozapine-treated schizophrenic cases (n = 17) and the remaining cases of schizophrenia treated with typical neuroleptics (n = 59) from an unselected, genera l population North Finland 1966 Birth Cohort: (n = 11,017). By the end of 1994, seventeen (22%) of a total 76 DSM-III-R schizophrenia patien ts, had received clozapine treatment. The mean length at birth was 52 cm in the clozapine group tin the non-clozapine group 50 cm) and corre spondingly the mean one year weight 10.4 kg (9.8 k:g), with the differ ences between the groups being statistically significant (P < 0.05). O ther pregnancy, delivery, and socio-demographic characteristics were, however, similar in the clozapine-treated and the remaining cases with schizophrenia. There was no evidence that severe schizophrenia requir ing treatment with clozapine was associated with impaired intrauterine or post-natal development. Indeed, during the first years of life the former group was larger in terms of weight and length than those trea ted with typical neuroleptics. These early developmental characteristi cs did not predict clinical severity of schizophrenia in adulthood. (C ) 1998 Elsevier Science Ltd. All rights reserved.